From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States
Drugs | Total | Total off-label (%) | BC specific off-label | Level of evidence | Primary ICD9 diagnosis code other than BC |
---|---|---|---|---|---|
Vinorelbine | 732 | 413 (27.0%) | 395 | Sufficient | 147, 184.4, 188, 202.8, 204.1 |
Carboplatin | 444 | 382 (25.0%) | 338 | Limited | 147, 162, 182, 191, 202.88, 235.7 |
Bevacizumab | 132 | 199 (13.0%) | 222 | Limited | 162.9, 184.4, 191.92, 202.8 |
Leuprolide | 136 | 133 (8.7%) | 122 | Limited | 171, 173.3 |
Liposomal Doxorubicin | 104 | 67 (4.4%) | 59 | Limited | 162.8, 171.9, 202.8 |
Cisplatin | 68 | 48 (3.1%) | 23 | Limited | 149.8, 150, 151, 162, 170.3, 173.3, 182, 195.0, 201, 202.8, 203, |